În contextul dificultăților de abordare terapeutică a pacienților cu psoriazis, vă prezentăm mai jos o trecere în revistă a unor studii contemporane, având drept obiectiv îmbunătățirea managementului clinic, de diagnostic și tratament al acestei afecțiuni.

  • Psoriasis Treatment Center of New Jersey Reports Positive Results for Tapinarof in Psoriasis Trial

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/psoriasis-treatment-center-of-new-jersey-reports-positive-results-for-tapinarof-in-psoriasis-trial

  • UCB’s Bimekizumab is Now Available

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/ucb-s-bimekizumab-is-now-available

  • FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/fda-approves-bimekizumab-for-moderate-to-severe-plaque-psoriasis

  • Arcutis Presents Positive Roflumilast Foam Data From ARRECTOR Trial in Scalp and Body PsO at EADV

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/arcutis-presents-positive-roflumilast-foam-data-from-arrector-trial-in-scalp-and-body-pso-at-eadv

  • Interim Data From Almirall’s POSITIVE Study Reveals Significant Well-Being Improvements Among Psoriasis Patients

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/interim-data-from-almirall-s-positive-study-reveals-significant-well-being-improvements-among-psoriasis-patients

  • Bristol Myers Squibb Presents 3-Year Safety and Efficacy Data of Deucravacitinib for PsO at EADV

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/bristol-myers-squibb-presents-3-year-safety-and-efficacy-data-of-deucravacitinib-for-pso-at-eadv

  • AnaptysBio Releases Positive Top-Line Phase 3 Results of Imsidolimab for GPP Flares

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/anaptysbio-releases-positive-top-line-phase-3-results-of-imsidolimab-for-gpp-flares

  • JNJ-2113 Advances in Clinical Development Programs for Plaque Psoriasis, Ulcerative Colitis

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/jnj-2113-advances-in-clinical-development-programs-for-plaque-psoriasis-ulcerative-colitis

  • FDA Approves Roflumilast Cream 0.3% In Children 6 to 11 Years With PsO

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/fda-approves-roflumilast-cream-0-3-in-children-6-to-11-years-with-pso

  • Risankizumab Efficacious in Patients With Concomitant Psoriasis and HIV, Study Reports

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/risankizumab-efficacious-in-patients-with-concomitant-psoriasis-and-hiv-study-reports

  • SARS-CoV-2 Associated With Increased Incidence of Psoriasis

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/sars-cov-2-associated-with-increased-incidence-of-psoriasis?fbclid=IwAR25dEf2QTSX9fjqTjpXqbRrZRm3sgg2wxxRsmR7VIFMHWTK08MEypKpVSw

  • Severe Psoriasis Associated With Higher Risk of Heart Disease

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/severe-psoriasis-associated-with-higher-risk-of-heart-disease

  • Dermoscopy Aids in Diagnosing Psoriasis Vulgaris and Nail Psoriasis

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/dermoscopy-aids-in-diagnosing-psoriasis-vulgaris-and-nail-psoriasis

  • Epidermal AXL Expression Lower in Psoriatic Skin

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/epidermal-axl-expression-lower-in-psoriatic-skin

  • Infection Risk Lower With IL-23i and IL-17i Than With TNFi in Psoriasis

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/infection-risk-lower-with-il-23i-and-il-17i-than-with-tnfi-in-psoriasis

  • Assessing the Relationship between Psoriasis and Psoriatic Arthritis

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/assessing-the-relationship-between-psoriasis-and-psoriatic-arthritis?utm_source=twitter&utm_medium=social&utm_campaign=Sponsored-Article_Aug23

Lectură plăcută!

  • Alte noutăți:

Review of Dermatology Times: ce este nou în acnee? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-acnee/

Review of Dermatology Times: ce este nou în rozacee? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-rozacee/

Review of Dermatology Times: ce este nou în vitiligo? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-vitiligo/

Review of Dermatology Times: ce este nou în alopecii? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-alopecii/

Review of Dermatology Times: ce este nou în medicina estetică? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-medicina-estetica/

Review of Dermatology Times: ce este nou în melasmă? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-melasma/

Review of Dermatology Times: ce este nou în dermatita seboreică? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-dermatita-seboreica/

Review of Dermatology Times: ce este nou în dermatita atopică? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-dermatita-atopica/

Review of Dermatology Times: ce este nou în hidrosadenita supurativă? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-hidrosadenita-supurativa/

Review of Dermatology Times: ce este nou în prurigo nodularis? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-prurigo-nodularis/

Review of Dermatology Times: ce este nou în tumorile cutanate? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-tumorile-cutanate/